来源：市场资讯（来源：BBW咏竹坊）彭博社周五援引知情人士消息报道，抗癌疗法研发企业传奇生物科技股份有限公司（LEGN.US）正考虑通过二次上市，潜在地点包括香港、新加坡及伦敦。传奇生物将成为赴港二次上市中概股的最新成员，多数企业选择香港上市，以对冲中美关系风险。传奇生物由金斯瑞生物科技（1548.HK）创建，后者至今仍持有其48%股权，总部位于美国新泽西州，业务遍及中国。传奇生物认为二次上市或可...
Source Link来源：市场资讯（来源：BBW咏竹坊）彭博社周五援引知情人士消息报道，抗癌疗法研发企业传奇生物科技股份有限公司（LEGN.US）正考虑通过二次上市，潜在地点包括香港、新加坡及伦敦。传奇生物将成为赴港二次上市中概股的最新成员，多数企业选择香港上市，以对冲中美关系风险。传奇生物由金斯瑞生物科技（1548.HK）创建，后者至今仍持有其48%股权，总部位于美国新泽西州，业务遍及中国。传奇生物认为二次上市或可...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.